Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  SanBio Co Ltd    4592   JP3336750009

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

SanBio : Names Mohammad El-Kalay New Technical Operations SVP

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/25/2017 | 06:58pm CET

SanBio, Inc., a leader in regenerative cell therapies, today announced the appointment of Mohammad El-Kalay, PhD, as Senior Vice President of Technical Operations. In this role, Dr. El-Kalay will be responsible for all technical operations, from process development, production, and supply chain management, to quality control and quality assurance.

Dr. El-Kalay has one of the industry’s most extensive backgrounds in the development and manufacturing of cell therapies. He served as a key team member in pioneering companies such as Applied Immune Sciences, Systemix, and Osiris Therapeutics, then led technical operations teams in Vice President roles at Morphogen Pharmaceuticals, Telos Pharmaceuticals, and MicroIslet. In 2006, Dr. El-Kalay founded a cellular therapy company EyeCyte, focusing on retinal diseases, and served as its Chief Executive Officer until 2013. More recently, he served as Vice President of Process Development and Manufacturing at StemCells, Inc. and as Vice President of Technical Operations at Sangamo Therapeutics.

"My passion is in cellular therapies, and my entire career has been devoted to realizing the huge potential of this technology," said El-Kalay. "SanBio’s clinical results are very promising, and its vision to bring cellular therapies into large-scale commercial application using allogeneic methods, is exactly the right direction for the industry."

A PhD chemical/biomedical engineer from Strathclyde University, Glasgow, Dr. El-Kalay has repeatedly established production processes and GMP manufacturing at a number of companies, bringing cellular therapies from preclinical stage to Phase 1, Phase 2, and Phase 3 clinical trials.

"We're delighted to welcome Mohammad," said Keita Mori, SanBio's Chief Executive Officer. "I have never encountered a technical operations executive with such deep experience in cell therapy processing and manufacturing. Mohammed’s deep scientific understanding, plus his extensive real-world experience, makes him the ideal executive to lead our technical operations and make SanBio’s vision of scalable cellular therapies a reality."

"SanBio has always maintained that allogeneic cell lines, with their consistent quality, rapid delivery, and excellent cost-effectiveness, offer tremendous practical advantages in commercial rollout," continued Mr. Mori. "The rest of the industry is only now appreciating these benefits, and we think we are years ahead on practical implementation. Mohammed’s presence at SanBio brings the day closer when patients everywhere can benefit from the great promise of regenerative medicine."

About SanBio, Inc. (SanBio)
SanBio is a regenerative medicine company headquartered in Tokyo, Japan, and Mountain View, California, with cell-based products in various stages of research, development, and clinical trials. Its proprietary cell-based product, SB623, is currently in a Phase 2b clinical trial for treatment of chronic motor impairments resulting from stroke with its joint development partner, Sumitomo Dainippon Pharma Co., Ltd., in the United States and Canada. SanBio is also implementing a global Phase 2 clinical trial in the United States and Japan using SB623 for treatment of motor impairment resulting from traumatic brain injury. More information about SanBio, Inc. is available at http://sanbio.com.


© Business Wire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANBIO CO LTD
09/25 SANBIO : Names Mohammad El-Kalay New Technical Operations SVP
09/07SANBIO CO LTD : half-yearly earnings release
07/17 SANBIO : $150 000 shot in the arm for STEM
06/29 SANBIO : South Africa finals of FemBioBiz Acceleration Competition today
04/20 SANBIO : BIH, NEPAD welcome applications for funding
03/14SANBIO CO LTD : annual earnings release
02/27 SANBIO : Study of SanBio's Stem Cell Treatment for Stroke Receives Innovation Aw..
02/24 SANBIO : New FemBioBiz Acceleration Programme to boost women in biosciences
2016SANBIO CO LTD : quaterly earnings release
2016SANBIO CO LTD : half-yearly earnings release
More news
News from SeekingAlpha
2016 Picking Winners Still Possible In Q1
Financials ( JPY)
Sales 2018 605 M
EBIT 2018 -
Net income 2018 -2 717 M
Finance 2018 2 143 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 187x
EV / Sales 2019 38,6x
Capitalization 115 B
Chart SANBIO CO LTD
Duration : Period :
SanBio Co Ltd Technical Analysis Chart | 4592 | JP3336750009 | 4-Traders
Technical analysis trends SANBIO CO LTD
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 2 404  JPY
Spread / Average Target -5,1%
EPS Revisions
Managers
NameTitle
Keita Mori President & Representative Director
Toru Kawanishi Chairman
Damien Bates Chief Medical Officer & Head-Development
Noboru Kotani Independent Outside Director
Mohammad A. El-Kalay Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
SANBIO CO LTD96.66%1 023
GILEAD SCIENCES1.16%94 601
REGENERON PHARMACEUTICALS6.67%42 072
VERTEX PHARMACEUTICALS100.10%37 280
GENMAB4.43%11 878
EXELIXIS, INC.76.93%7 805